Vertex nabs rights to cystic fibrosis molecules
Tuesday, June 9, 2015 - 11:01
in Health & Medicine
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs